Sponsorship Information

One of the major aspects of anti-counterfeiting and brand protection for pharmaceuticals is the implementation of serialization along the supply chain. Ahead of the 7th Pharma Anti-Counterfeiting & Brand Protection summit, we examined the role that serialization challenges play on counterfeiting in pharmaceuticals, as well as sessions from the upcoming event that can help to provide more insight. To learn more about these challenges, as well as specifics regarding our corresponding sessions, make sure to download the report.

How can the patient be sure the medication he/she is going to take is exactly what the doctor ordered? Every year, substandard, spurious, falsely-labeled, falsified and counterfeit drugs work their way into the market and eventually into the homes and hands of pateitns treating everything from routine illnesses to chronic conditions. If you would prefer to receive a copy instead, please email Max.Miller@iqpc.com

The 7th Annual Anti-Counterfeiting for Pharmaceuticals Summit takes a comprehensive approach to understand the latest regulations for the DSCSA to remain compliant and uphold quality throughbrand protections plans and anti-counterfeiting strategies. Get your copy of the preliminary draft agenda! Or have it sent to your inbox by emailing max.miller@iqpc.com

Developing countries are the worst affected from counterfeit
pharmaceuticals, regulatory structures are weaker and measurement and
oversight is difficult. According to the World Health Organization, an
estimated 1 in 10 medical products in low- and middle-income countries
is substandard or falsified. This heat map specifically focuses in on
the largest counterfeiting markets: Africa, China, and India. Download
this map to learn about the latest advancements developing countries
have taken to combat anti-counterfeiting and which country needs
to start making it a priority.